Drug Trial Radar · NCT07323095
Evaluate the Efficacy and Safety of ABP-671 in Subjects With Chronic Kidney Disease and Hyperuricaemia
Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
80
Planned (sponsor's estimate)
Start
Oct 2, 2026
Primary completion
Oct 31, 2027
Study completion Jan 31, 2028
Sponsor
- Lead sponsor
- Atom Therapeutics Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Jan 7, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 2, international, multicenter, randomized, double blind, placebo-controlled trial to evaluate the efficacy and safety of ABP-671 in subjects with CKD and hyperuricaemia, to preliminarily evaluate the efficacy of ABP-671 in the treatment of subjects with CKD and hyperuricemia, primary Efficacy Endpoint is change in UACR from baseline to Week 40
Conditions
- Chronic Kidney Disease
Interventions
ABP-671 plus febuxostat Group 1Drug
ABP-671 Dose 1 + Febuxostat Dose 1-tablets(PO)
ABP-671 plus febuxostat Group 2Drug
ABP-671 Dose 2 + Febuxostat Dose 2-tablets(PO)
ABP-671 GroupDrug
ABP-671 Dose 2 + Febuxostat placebo-tablets(PO)
Placebo GroupDrug
ABP-671 placebo-tablets(PO) + Febuxostat placebo-tablets(PO)
Primary outcomes
What the sponsor says the trial is designed to measure.
- The change in the urine albumin-to-creatinine ratio (mg/g) as reported in the laboratory report compared to the baselineTime frame: Week 40
Locations
10 sites in 2 countries. Site status is shown where the registry gives one.
Renal Research Gosford Pty Ltd
Gosford, New South Wales, Australia · Not yet recruiting
Genesis Research services
Newcastle, New South Wales, Australia · Recruiting
Paratus Clinical Research Brisbane
Brisbane, Queensland, Australia · Recruiting
Beijing Tsinghua Changgung Hospital
Beijing, Beijing Municipality, China · Not yet recruiting
Peking University First Hospital
Beijing, Beijing Municipality, China · Not yet recruiting
Xuanwu Hospital Capital Medical University
Beijing, Beijing Municipality, China · Not yet recruiting
Jiangsu Province Hospital
Nanjing, Jiangsu, China · Not yet recruiting
Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, China · Not yet recruiting
Sir Run Run Shaw Hospital , affiliated with the Zhejiang University School of Medicine
Hangzhou, Zhejiang, China · Not yet recruiting
Zhejiang Provincial People's Hospital
Hangzhou, Zhejiang, China · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.